Founded in 1981, it is a high-tech enterprise integrating R&D/production/sales/service of specialized veterinary biological products, Shanghai famous brand, listed company, production base of veterinary biological products and animal major epidemic prevention and control drugs
Shanghai Haili Biotechnology Co., Ltd. (SH: 603718) (hereinafter referred to as the "Company") is a professional veterinary biological products manufacturer integrating R&D, production, sales and service. The company was founded in 1981, and its predecessor was Shanghai Songjiang Biopharmaceutical Factory. The company is the Ministry of Agriculture in Shanghai approved the production of veterinary biological products designated enterprises and the Ministry of Agriculture in Shanghai set up a major animal epidemic prevention and control production base, the company has a complete product line, perfect product structure, with poultry, livestock, pets three categories of a total of 44 products, with a full range of service product base and capabilities. In May 2015, the company successfully landed on the domestic A-share main board market, with a total share capital of 644 million shares.
The company is a high-tech enterprise in Shanghai, a key high-tech enterprise in the National Torch Program, a key leading enterprise in agricultural industrialization in Shanghai, a civilized unit in Shanghai, a contract-abiding and trustworthy enterprise in Shanghai, and the enterprise R&D center has been identified as Shanghai Enterprise Technology Center, Shanghai Veterinary Biological Products Engineering Technology Research Center, Shanghai Veterinary Vaccine Manufacturing Process Professional Technical Service Platform, Shanghai Academician Expert Workstation, the company has 24 registered trademarks, among which Haili biological trademark has been identified as a famous trademark in Shanghai. The company's pig vaccine products won the title of "Shanghai Famous Brand"; The company has veterinary drug GMP certificate, veterinary drug production license, laboratory animal license, veterinary drug business license and other production and operation qualification certificates, has 11 GMP production lines, and independently produces two series of vaccine products for livestock and poultry.
The company is committed to building a scientific research system combining independent research and development and industry-university-research cooperation, and has established stable cooperative relations with scientific research institutions and universities such as China Institute of Veterinary Drug Control, Chinese Academy of Sciences, Shanghai Academy of Agricultural Sciences, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Beijing Academy of Agriculture and Forestry Sciences, Jiangsu Academy of Agricultural Sciences, Nanjing Agricultural University, Henan Agricultural University, Huazhong Agricultural University, Zhejiang University, Jiangxi Agricultural University and other scientific research institutions and universities. In the field of veterinary vaccines, a number of industry-leading non-patented technologies have been obtained, and the transformation of high-tech achievements has been rapidly realized.
Since its establishment, the company has adhered to the road of scientific and technological innovation, market-oriented, product-based, sales network all over the country, and sales performance has grown steadily. Adhering to the people-oriented talent strategy, we have established a market-oriented marketing team, a skilled R&D team and a skilled staff team. The company is committed to the prevention of livestock and poultry diseases, improve the health of livestock and poultry and improve the production efficiency of farmers, and can provide comprehensive solutions and authoritative veterinary expert service system. In order to meet the market demand, the company will, as always, adhere to the strategic focus of independent innovation and high-tech industrialization development, and strive to be among the forefront of the domestic animal health industry.
In recent years, the company has also been actively exploring the terminal market, promoting the progress of new product research and development, the implementation of new process transformation, accelerating the construction of new vaccine production facilities, improving the company's core competitiveness, and continuously carrying out in-depth cooperation with global industry leaders. Yangling Jinhai Biotechnology Co., Ltd., a joint venture between the company and the Argentine Biogénse Bagó S.A. (hereinafter referred to as "BB"), one of the world's largest manufacturers of foot-and-mouth disease vaccines, will adopt BB's most advanced and stable full-suspension and high-purification production technology for the production of foot-and-mouth disease vaccines, and its process scale technology level ranks among the top in the global industry. At the same time, the company actively carries out foreign investment, and actively implements the two-wheel drive layout of "animal protection and human insurance", and the main investment companies are Shanghai Xukang Medical Technology Co., Ltd. and Shanghai Yulon Biotechnology Co., Ltd. In 2017, the company initiated the establishment of Shanghai Runling Investment Partnership (Limited Partnership), which will provide more channels and reserve projects for the company's expansion in the field of "PICC", which is conducive to the company's strengthening and expansion on a broader platform.
